Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane-Reference-Cited by-同舟云学术

Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane

Published:2018-05 Issue:5 Volume:29 Page:1195-1202
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Martin M.,Campone M.,Bondarenko I.,Sakaeva D.,Krishnamurthy S.,Roman L.,Lebedeva L.,Vedovato J.-C.,Aapro M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/5/1195/24831754/mdy063.pdf

Reference24 articles.

1. Socioeconomic inequalities in breast cancer incidence and mortality in Europe-a systematic review and meta-analysis;Lundqvist;Eur J Public Health,2016

2. European cancer mortality predictions for the year 2017, with focus on lung cancer;Malvezzi;Ann Oncol,2017

3. Global cancer incidence and mortality rates and trends – an update. Cancer;Torre;Epidemiol Biomarkers Prev,2016

4. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer;Miller;J Clin Oncol,2005

5. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer;Barrios;Breast Cancer Res Treat,2010

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Third-line Treatment for Metastatic Triple-negative Breast Cancer;American Journal of Clinical Oncology;2023-12-15

2. Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study;Surgery Open Science;2023-12

3. Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18F-FES PET;Cancers;2022-07-20

4. The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC;Clinical Breast Cancer;2021-10

5. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer;Cancer Research and Treatment;2021-07-15